Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
TG Therapeutics, Inc. (TGTX) had Normalized Income after Taxes of $23.04M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$192.57M |
|
$23.04M |
|
$38.14M |
|
$154.43M |
|
$142.08M |
|
$50.49M |
|
$-5.40M |
|
$45.09M |
|
$45.09M |
|
$23.04M |
|
$23.04M |
|
$23.04M |
|
|
Normalized Income after Taxes |
$23.04M |
$50.49M |
|
-- |
|
142.96M |
|
159.37M |
|
$0.16 |
|
$0.14 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|